tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Nakajima K et al. | Effects of triple therapy of cyclosporine, FK 506, and RS-61443 on allogeneic small bowel transplantation in dogs. | 1993 | Transplant. Proc. | pmid:7679821 |
| Tzakis AG et al. | Two-year experience with FK 506 in pediatric patients. | 1993 | Transplant. Proc. | pmid:7679822 |
| Gibbs JF et al. | Outcome analysis of FK 506 therapy for acute and chronic rejection. | 1993 | Transplant. Proc. | pmid:7679823 |
| Morphological characteristics of renal allografts showing renal dysfunction under FK 506 therapy: is graft biopsy available to reveal the morphological findings corresponding with FK 506 nephropathy? Japanese FK 506 Study Group. | 1993 | Transplant. Proc. | pmid:7679824 | |
| Alessiani M et al. | Adverse effects of FK 506 overdosage after liver transplantation. | 1993 | Transplant. Proc. | pmid:7679825 |
| McCauley J et al. | FK 506 in the management of nephrotic syndrome after renal transplantation. | 1993 | Transplant. Proc. | pmid:7680154 |
| Mañez R et al. | Association between donor-recipient HLA-DR compatibility and cytomegalovirus hepatitis and chronic rejection in liver transplantation. | 1993 | Transplant. Proc. | pmid:7680170 |
| McCauley J | The nephrotoxicity of FK506 as compared with cyclosporine. | 1993 | Curr. Opin. Nephrol. Hypertens. | pmid:7532089 |
| Woan MC et al. | Characterization of the biopsy growth assay in monitoring cardiac transplant patients for rejection. | 1993 | Transplant. Proc. | pmid:7680171 |
| Rilo HR et al. | Effect of intraportal human islet transplantation on kidney graft survival in simultaneous kidney-islet allografts. | 1993 | Transplant. Proc. | pmid:7680172 |
| Fukuzaki T et al. | Induction of unresponsiveness to islet allograft by preoperative donor spleen cell injection and FK 506 treatment. | 1993 | Transplant. Proc. | pmid:7680173 |
| Schweizer M et al. | Sensitivity of mitochondrial peptidyl-prolyl cis-trans isomerase, pyridine nucleotide hydrolysis and Ca2+ release to cyclosporine A and related compounds. | 1993 | Biochem. Pharmacol. | pmid:7680201 |
| Deardon DJ et al. | Small bowel tonometry: a possible technique for detecting early small bowel allograft dysfunction. | 1993 | Transplant. Proc. | pmid:7505502 |
| Demetris AJ et al. | Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. | 1993 | Transplant. Proc. | pmid:7505503 |
| Pancer Z et al. | cDNA cloning of a putative protochordate FK506-binding protein. | 1993 | Biochem. Biophys. Res. Commun. | pmid:7505578 |
| Woodle ES et al. | Recurrent rejection following FK 506 rescue therapy for acute hepatic allograft rejection. | 1993 | Transplant. Proc. | pmid:7682358 |
| Fischer S et al. | A mechanism for rotamase catalysis by the FK506 binding protein (FKBP). | 1993 | Biochemistry | pmid:7505615 |
| Woodle ES et al. | FK 506 rescue therapy: early conversion improves efficacy. | 1993 | Transplant. Proc. | pmid:7682359 |
| Woodle ES et al. | FK 506 rescue therapy: the rapidity of rejection reversal is related to the subsequent development of CMV disease. | 1993 | Transplant. Proc. | pmid:7682360 |
| Meiser BM et al. | Simvastatin decreases accelerated graft vessel disease after heart transplantation in an animal model. | 1993 | Transplant. Proc. | pmid:7682363 |
| Yu Y et al. | Mutagenicity of the new immunosuppressive drugs, FK 506, and spergualin. | 1993 | Transplant. Proc. | pmid:7682364 |
| McCauley J et al. | Pilot trial of FK 506 in the management of steroid-resistant nephrotic syndrome. | 1993 | Nephrol. Dial. Transplant. | pmid:7508098 |
| Schmitt J et al. | Cloning and expression of a mouse cDNA encoding p59, an immunophilin that associates with the glucocorticoid receptor. | 1993 | Gene | pmid:7693550 |
| Nishikawa T et al. | Kinetic analysis of molecular interconversion of immunosuppressant FK506 by high-performance liquid chromatography. | 1993 | Pharm. Res. | pmid:7508108 |
| Shafiee A et al. | Enzymatic synthesis and immunosuppressive activity of novel desmethylated immunomycins (ascomycins). | 1993 | J. Antibiot. | pmid:7693638 |
| Keicho N et al. | Antilymphocytic activity of erythromycin distinct from that of FK506 or cyclosporin A. | 1993 | J. Antibiot. | pmid:7693639 |
| Timerman AP et al. | The calcium release channel of sarcoplasmic reticulum is modulated by FK-506-binding protein. Dissociation and reconstitution of FKBP-12 to the calcium release channel of skeletal muscle sarcoplasmic reticulum. | 1993 | J. Biol. Chem. | pmid:7693682 |
| Schwaninger M et al. | Inhibition of cAMP-responsive element-mediated gene transcription by cyclosporin A and FK506 after membrane depolarization. | 1993 | J. Biol. Chem. | pmid:7693684 |
| Takeda Y et al. | Stimulation of endothelin mRNA and secretion in human endothelial cells by FK 506. | 1993 | J. Cardiovasc. Pharmacol. | pmid:7509973 |
| Soldin SJ et al. | Immunophilin receptors for immunosuppressive drugs. | 1993 | Ther Drug Monit | pmid:7510077 |
| Connelly PR et al. | Probing hydration contributions to the thermodynamics of ligand binding by proteins. Enthalpy and heat capacity changes of tacrolimus and rapamycin binding to FK506 binding protein in D2O and H2O. | 1993 | Biochemistry | pmid:7684925 |
| Wallemacq PE et al. | Improvement and assessment of enzyme-linked immunosorbent assay to detect low FK506 concentrations in plasma or whole blood within 6 hours. | 1993 | Clin. Chem. | pmid:7684956 |
| Mochizuki M et al. | A clinical trial of FK506 in refractory uveitis. | 1993 | Am. J. Ophthalmol. | pmid:7685147 |
| Ocain TD et al. | A nonimmunosuppressive triene-modified rapamycin analog is a potent inhibitor of peptidyl prolyl cis-trans isomerase. | 1993 | Biochem. Biophys. Res. Commun. | pmid:7685167 |
| Asami M et al. | Detection of the FK506-FKBP-calcineurin complex by a simple binding assay. | 1993 | Biochem. Biophys. Res. Commun. | pmid:7685169 |
| Renoir JM et al. | Immunological identification of a 50 kDa Mr FK506-binding immunophilin as a component of the non-DNA binding, hsp90 and hsp70 containing, heterooligomeric form of the chick oviduct progesterone receptor. | 1993 | C. R. Acad. Sci. III, Sci. Vie | pmid:7522118 |
| Jung-Testas I et al. | [Inhibition of the anti-glucocorticosteroid effect of RU486 on the growth of mouse fibroblasts in culture by the immunosuppressor kf506]]. | 1993 | C. R. Acad. Sci. III, Sci. Vie | pmid:7522119 |
| Nishizawa S et al. | Therapeutic effect of a new immunosuppressant, FK-506, on vasospasm after subarachnoid hemorrhage. | 1993 | Neurosurgery | pmid:7687044 |
| Warty V et al. | FK506 measurement: comparison of different analytical methods. | 1993 | Ther Drug Monit | pmid:7687389 |
| Iwata H et al. | Suppression of allograft responses by combining donor alloantigen-specific intravenous presensitization with suboptimal doses of FK506. | 1993 | Transplantation | pmid:7687396 |
| Roelen DL et al. | Differential inhibition of primed alloreactive CTLs in vitro by clinically used concentrations of cyclosporine and FK506. | 1993 | Transplantation | pmid:7687397 |
| Antoni FA et al. | Inhibitory role for calcineurin in stimulus-secretion coupling revealed by FK506 and cyclosporin A in pituitary corticotrope tumor cells. | 1993 | Biochem. Biophys. Res. Commun. | pmid:7687429 |
| Jost U et al. | FK 506 treatment of intractable rejection after liver transplantation. | 1993 | Transplant. Proc. | pmid:7689276 |
| Winkler M et al. | Plasma level-guided low-dose FK 506 therapy in patients with early liver dysfunction after liver transplantation. | 1993 | Transplant. Proc. | pmid:7689277 |
| Viebahn R et al. | Simulation of hypoxic and preservation injury in human hepatocyte cultures: influence of FK 506 and cyclosporine. | 1993 | Transplant. Proc. | pmid:7689278 |
| Dé P et al. | Early steroid-resistant rejection following orthotopic liver transplantation: new aspects of treatment with FK 506 instead of OKT3? | 1993 | Transplant. Proc. | pmid:7689279 |
| Ueda D et al. | Influence of FK 506 on renal blood flow. | 1993 | Transplant. Proc. | pmid:7689280 |
| Lee KK et al. | Successful treatment of ongoing intestinal allograft rejection permits recovery of graft structure and function. | 1993 | Am. J. Surg. | pmid:7678188 |
| Galvin F et al. | Effects of cyclosporin A, FK 506, and mycalamide A on the activation of murine CD4+ T cells by the murine B7 antigen. | 1993 | Eur. J. Immunol. | pmid:7678228 |
| Foxwell BM et al. | Inhibition of activation-induced changes in the structure of the T cell interleukin-7 receptor by cyclosporin A and FK506. | 1993 | Eur. J. Immunol. | pmid:7678231 |